文献速递白血病

中国儿童急性淋巴细胞白血病患者接受PEG-门冬酰胺酶后门冬酰胺酶活性水平与临床特征及不良反应的相关性

The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2024-06-27

研究监测329例接受CCCG-ALL-2015/CCCG-ALL-2020方案治疗的中国儿童急性淋巴细胞白血病患者的门冬酰胺酶活性(AEA),共2147份样本。第7±1天平均AEA为931 iu/L(654-1174 iu/L),第14±1天为664 iu/L(463-860 iu/L);PEG-门冬酰胺酶失活率为19.1%,沉默性失活率为12.5%。除低纤维蛋白原血症外,AEA升高未增加PEG-门冬酰胺酶相关不良反应风险。

要点

  • 第7±1天平均AEA 931 iu/L(654-1174 iu/L),第14±1天664 iu/L(463-860 iu/L)。
  • PEG-门冬酰胺酶失活率19.1%,沉默性失活率12.5%,9例出现过敏样反应。
  • 除低纤维蛋白原血症外,AEA升高未增加PEG-门冬酰胺酶相关不良反应风险。

核心结论

  • 除低纤维蛋白原血症外,AEA水平升高未增加PEG-门冬酰胺酶相关不良反应风险。
  • 药物监测可用于指导治疗决策,个体化门冬酰胺酶剂量不降低毒性。
  • PEG-门冬酰胺酶的治疗目标仍是达到持续且充分的活性。

研究设计与样本

  • 监测接受CCCG-ALL-2015/CCCG-ALL-2020方案治疗的儿童急性淋巴细胞白血病患者的AEA。
  • 共测量329例患者的2147份样本,检测时间为第7±1天和第14±1天。
  • 分析AEA与患者特征及PEG-门冬酰胺酶相关不良反应的关联。

主要发现

  • 第7±1天平均AEA为931 iu/L(四分位距654-1174 iu/L),第14±1天为664 iu/L(463-860 iu/L)。
  • AEA水平在年幼儿童中更高,并随累积剂量次数增加而升高。
  • PEG-门冬酰胺酶失活率为19.1%,沉默性失活率为12.5%,9例患者出现过敏样反应。
  • 低纤维蛋白原血症、高甘油三酯血症、胰腺炎和血栓形成与年龄较大相关,低血糖与年龄较小相关。
  • 高甘油三酯血症和低血糖风险随PEG-门冬酰胺酶累积剂量次数增加而升高。

临床怎么用

  • 药物监测可用于指导治疗决策。
  • 个体化门冬酰胺酶剂量不降低毒性。
  • PEG-门冬酰胺酶的治疗目标仍是达到持续且充分的活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Studies on asparaginase enzyme activity (AEA) monitoring in Chinese patients receiving PEG-asparaginase remain limited. We monitored AEA in paediatric patients diagnosed with acute lymphoblastic leukaemia (ALL) and treated according to the Chinese Children's Cancer Group study protocols, CCCG-ALL-2015/CCCG-ALL-2020 protocols. We measured the AEA at days 7 ± 1 and 14 ± 1 and analysed their association with patient characteristics and PEG-asparaginase-related adverse effects (AEs). We measured 2147 samples from 329 patients. Mean AEA levels (interquartile range) were 931 iu/L (654-1174 iu/L) at day 7 ± 1 and 664 iu/L (463-860 iu/L) at day 14 ± 1. The AEA levels were higher in younger children and increased with the cumulative dose numbers. PEG-asparaginase inactivation rate was 19.1%, and the silent inactivation (SI) rate was 12.5%. Nine patients were identified with allergic-like reactions. Hypofibrinogenaemia, hypertriglyceridaemia, pancreatitis and thrombosis were associated with older age, whereas hypoglycaemia was associated with younger age. The risk of hypertriglyceridaemia and hypoglycaemia increased with cumulative dose numbers of PEG-asparaginase. Except for hypofibrinogenaemia, elevated AEA levels did not increase the risk of PEG-asparaginase-related AEs. Drug monitoring can be utilized as guidance for treatment decision-making. Individualizing asparaginase doses do not reduce toxicities. The treatment target of PEG-asparaginase remains to achieve sustained and adequate activity.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen C, Li J, Chen Y, et al. The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia. Br J Haematol. 2024. PMID: 38934331. doi:10.1111/bjh.19605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。